A newly developed digital patient decision aid designed to support treatment choices in inflammatory bowel disease demonstrated good usability and acceptability during alpha testing with patients and clinicians, according to findings published in BMC Medical Informatics and Decision Making. The web-based application, designated I(BD) SELECT, was systematically developed to assist individuals facing complex, preference-sensitive choices regarding their long-term disease management, specifically regarding the initiation or switching of advanced therapies.
The study focused on addressing decisional needs within the Belgian healthcare context, where the expanding availability of therapeutic options has made long-term inflammatory bowel disease management increasingly preference-sensitive. Although professional recommendations advocate for shared decision making to align clinical treatment plans with personal patient values, practical tools designed to facilitate shared decision making in this clinical domain remain limited.
To construct the decision aid, the research team followed a multi-phase, user-centered design process aligned with the International Patient Decision Aid Standards guidance. During the initial development phase, researchers explored decisional requirements by conducting semi-structured interviews with 15 patients living with inflammatory bowel disease and 23 practicing healthcare professionals to determine the essential scope, structure, and clinical content of the tool.
Findings from the initial needs assessment identified the initiation of advanced therapies and switching between them as central preference-sensitive decisions, which subsequently established the operational scope of the platform. Based on this evidence, the team developed an evidence-informed digital prototype that incorporated a discrete choice experiment intended to serve as a structured values clarification exercise for users.
The resulting web-based decision aid delivers tailored treatment information and generates an individualized preference summary derived from patient responses to the discrete choice experiment. To assess its functional performance, investigators conducted iterative alpha testing with a separate cohort comprising 17 patients and 18 healthcare professionals. These evaluators engaged in think-aloud evaluation sessions, semi-structured interviews, and standardized usability questionnaires, yielding an overall mean System Usability Scale score of 78.9 out of 100.
Participants indicated that they valued the balanced presentation of information alongside the personalized preference summaries, noting that the system helped them reflect on their treatment preferences and could assist in preparing for clinical consultations. Feedback gathered during testing highlighted specific areas for refinement, which focused primarily on user navigation and textual wording. The authors noted that these qualitative and quantitative suggestions were incorporated iteratively into the prototype’s revised interface.
Most participating patients and healthcare professionals indicated a clear willingness to use the digital decision aid within routine clinical practice. The authors concluded that combining tailored clinical information with structured preference elicitation offers a promising method to enhance shared decision making in inflammatory bowel disease care, noting that active field testing is currently underway to evaluate the tool’s practical feasibility, clinical effectiveness, and broader impact in routine healthcare environments.
The structured multi-phase development strategy adhered to International Patient Decision Aid Standards guidance to ensure rigorous creation of the digital tool. By pairing tailored treatment information with a discrete choice experiment, the prototype operationalized values clarification to help users consider their personal priorities. Qualitative and quantitative findings gathered from think-aloud sessions, usability questionnaires, and semi-structured interviews continuously guided iterative refinements, allowing developers to improve textual wording and interface navigation based on direct user input.
Although alpha testing confirmed that the decision aid is usable and acceptable among both patients and healthcare professionals, comprehensive clinical evaluation remains an active next phase. Investigators are currently conducting field testing to evaluate the platform’s clinical effectiveness, practical feasibility, and overall impact within routine healthcare settings. This ongoing research will determine how successfully structured preference elicitation supports shared decision making during actual clinical practice.
Subject of Research: Digital patient decision aid usability for inflammatory bowel disease treatment decisions
Article Title: Development and usability testing of I(BD) SELECT: a digital patient decision aid for advanced therapy decisions in inflammatory bowel disease
Article References: Schoefs, E., Vandebroek, M., Ferrante, M., Verstockt, B., Sabino, J., Debrun, L., Lambrechts, T., Michiels, L., Lenaerts, S., Van Aerschot, A., Van Audenhove, C., Straetemans, N., Vermeire, S., & Huys, I. (2026). Development and usability testing of I(BD) SELECT: a digital patient decision aid for advanced therapy decisions in inflammatory bowel disease. BMC Medical Informatics and Decision Making. https://doi.org/10.1186/s12911-026-03939-7
Image Credits: AI Generated
DOI: 10.1186/s12911-026-03939-7
Keywords: inflammatory bowel disease, patient decision aid, shared decision making, advanced therapies, discrete choice experiment, System Usability Scale, alpha testing, values clarification, think-aloud sessions, usability testing, IPDAS standards, preference-sensitive decisions, Belgian healthcare, digital health prototype, treatment decision support, clinical consultation preparation
News Source: Denise Maddox. (November 20, 2026). Digital Tool for Inflammatory Bowel Disease Therapy Demonstrates Good Usability in Testing. Scienmag.



